LncRNA FAM83H-AS1 contributes to the radioresistance, proliferation, and metastasis in ovarian cancer through stabilizing HuR protein

DOI: 10.1016/j.ejphar.2019.03.002
European Journal of Pharmacology, 2019, 852, 134-141.

#	Paper	IF	Citations
39	Downregulation of H19 decreases the radioresistance in esophageal squamous cell carcinoma cells. *OncoTargets and Therapy*, **2019**, 12, 4779-4788	4.4	7
38	FAM83H-AS1 is upregulated and predicts poor prognosis in colon cancer. *Biomedicine and Pharmacotherapy*, **2019**, 118, 109342	7.5	11
37	Knockdown of long non-coding RNA TINCR decreases radioresistance in colorectal cancer cells. *Pathology Research and Practice*, **2019**, 215, 152622	3.4	9
36	Serum LncRNA-ATB and FAM83H-AS1 as diagnostic/prognostic non-invasive biomarkers for breast cancer. *Life Sciences*, **2020**, 259, 118193	6.8	16
35	Knockdown of LINC00473 promotes radiosensitivity of non-small cell lung cancer cells via sponging miR-513a-3p. *Free Radical Research*, **2020**, 54, 756-764	4	3
34	FAM83H-AS1 is a potential modulator of cancer driver genes across different tumors and a prognostic marker for ER/PR + BRCA patients. *Scientific Reports*, **2020**, 10, 14145	4.9	2
33	Downregulation of lncRNA XIST Represses Tumor Growth and Boosts Radiosensitivity of Neuroblastoma via Modulation of the miR-375/L1CAM Axis. *Neurochemical Research*, **2020**, 45, 2679-2690	4.6	12
32	LncRNA FAM83H-AS1 maintains intervertebral disc tissue homeostasis and attenuates inflammation-related pain via promoting nucleus pulposus cell growth through miR-22-3p inhibition. *Annals of Translational Medicine*, **2020**, 8, 1518	3.2	4
31	The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis. *Cancer Cell International*, **2020**, 20, 72	6.4	8
30	Non-Coding RNAs in Cancer Radiosensitivity: MicroRNAs and lncRNAs as Regulators of Radiation-Induced Signaling Pathways. *Cancers*, **2020**, 12,	6.6	21
29	The Challenges and Opportunities of LncRNAs in Ovarian Cancer Research and Clinical Use. *Cancers*, **2020**, 12,	6.6	13
28	Long non-coding RNA FAM83H-AS1 as an emerging marker for diagnosis, prognosis and therapeutic targeting of cancer. *Cell Biochemistry and Function*, **2021**, 39, 350-356	4.2	1
27	Gynecologic cancers and non-coding RNAs: Epigenetic regulators with emerging roles. *Critical Reviews in Oncology/Hematology*, **2021**, 157, 103192	7	44
26	Long non-coding RNA FAM83H-AS1 acts as a potential oncogenic driver in human ovarian cancer. *Journal of Ovarian Research*, **2021**, 14, 6	5.5	2
25	A Novel Prognostic Model of Endometrial Carcinoma Based on Clinical Variables and Oncogenomic Gene Signature. *Frontiers in Molecular Biosciences*, **2020**, 7, 587822	5.6	5
24	The oncogenic and tumor suppressive roles of RNA-binding proteins in human cancers. *Journal of Cellular Physiology*, **2021**, 236, 6200-6224	7	9
23	A Novel Androgen-Induced lncRNA FAM83H-AS1 Promotes Prostate Cancer Progression the miR-15a/CCNE2 Axis. *Frontiers in Oncology*, **2020**, 10, 620306	5.3	1

22	Interaction Between LncRNA and UPF1 in Tumors. *Frontiers in Genetics*, **2021**, 12, 624905	4.5	3
21	Silencing of HuR Inhibits Osteosarcoma Cell Epithelial-Mesenchymal Transition AGO2 in Association With Long Non-Coding RNA XIST. *Frontiers in Oncology*, **2021**, 11, 601982	5.3	1
20	Non-Coding RNAs as Biomarkers of Tumor Progression and Metastatic Spread in Epithelial Ovarian Cancer. *Cancers*, **2021**, 13,	6.6	4
19	Long non-coding RNA AFAP1-AS1 facilitates ovarian cancer progression by regulating the miR-107/PDK4 axis. *Journal of Ovarian Research*, **2021**, 14, 60	5.5	4
18	Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives. *Cancer Letters*, **2021**, 502, 97-107	9.9	6
17	Long non-coding RNAs: A view to kill ovarian cancer. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2021**, 1876, 188584	11.2	4
16	The regulatory role of antisense lncRNAs in cancer. *Cancer Cell International*, **2021**, 21, 459	6.4	5
15	EZH2-mediated lncRNA ABHD11-AS1 promoter regulates the progression of ovarian cancer by targeting miR-133a-3p. *Anti-Cancer Drugs*, **2021**, 32, 269-277	2.4	2
14	LncRNA FAM83H-AS1 promotes triple-negative breast cancer progression by regulating the miR-136-5p/metadherin axis. *Aging*, **2020**, 12, 3594-3616	5.6	38
13	LINC00460 accelerates progression of ovarian cancer by activating transcriptional factor ZNF703. *Oncology Letters*, **2020**, 19, 4189-4194	2.6	2
12	LGFC-CNN: Prediction of lncRNA-Protein Interactions by Using Multiple Types of Features through Deep Learning. *Genes*, **2021**, 12,	4.2	1
11	Non-Coding RNAs Associated With Radioresistance in Triple-Negative Breast Cancer. *Frontiers in Oncology*, **2021**, 11, 752270	5.3	4
10	Development and Validation of a Novel Stemness-Index-Related Long Noncoding RNA Signature for Breast Cancer Based on Weighted Gene Co-Expression Network Analysis.. *Frontiers in Genetics*, **2022**, 13, 760514	4.5	1
9	Roles of Embryonic Lethal Abnormal Vision-Like RNA Binding Proteins in Cancer and Beyond.. *Frontiers in Cell and Developmental Biology*, **2022**, 10, 847761	5.7	0
8	LncRNAs as Theragnostic Biomarkers for Predicting Radioresistance in Cancer: A Systematic Review and Meta-Analysis. *Frontiers in Oncology*, **2022**, 12,	5.3	
7	LncRNA MIAT Promotes Spinal Cord Injury Recovery in Rats by Regulating RBFOX2-Mediated Alternative Splicing of MCL-1. *Molecular Neurobiology*,	6.2	
6	HuR Affects the Radiosensitivity of Esophageal Cancer by Regulating the EMT-Related Protein Snail. *Frontiers in Oncology*, 12,	5.3	
5	LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect □catenin from degradation. **2022**, 41,		0

4	Ovarian Cancer Radiosensitivity: What Have We Understood So Far?. **2023**, 13, 6	0
3	Diagnostic value of non-coding RNAs in ovarian cancer.	0
2	LINC00460 Promotes Cutaneous Squamous Cell Carcinoma Progression Through Stabilizing ELAVL1 Protein.	0
1	Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors. **2023**, 15, 1539	0